548 related articles for article (PubMed ID: 31827283)
1. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy.
Wei J; Long L; Zheng W; Dhungana Y; Lim SA; Guy C; Wang Y; Wang YD; Qian C; Xu B; Kc A; Saravia J; Huang H; Yu J; Doench JG; Geiger TL; Chi H
Nature; 2019 Dec; 576(7787):471-476. PubMed ID: 31827283
[TBL] [Abstract][Full Text] [Related]
2. PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.
Wiede F; Lu KH; Du X; Liang S; Hochheiser K; Dodd GT; Goh PK; Kearney C; Meyran D; Beavis PA; Henderson MA; Park SL; Waithman J; Zhang S; Zhang ZY; Oliaro J; Gebhardt T; Darcy PK; Tiganis T
EMBO J; 2020 Jan; 39(2):e103637. PubMed ID: 31803974
[TBL] [Abstract][Full Text] [Related]
3. Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL.
Zheng W; Wei J; Zebley CC; Jones LL; Dhungana Y; Wang YD; Mavuluri J; Long L; Fan Y; Youngblood B; Chi H; Geiger TL
Blood; 2021 Jul; 138(2):122-135. PubMed ID: 33690816
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc.
Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Kammula US
Cancer Res; 2015 Aug; 75(16):3216-26. PubMed ID: 26100671
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
Spranger S; Dai D; Horton B; Gajewski TF
Cancer Cell; 2017 May; 31(5):711-723.e4. PubMed ID: 28486109
[TBL] [Abstract][Full Text] [Related]
6. Runx3 programs CD8
Milner JJ; Toma C; Yu B; Zhang K; Omilusik K; Phan AT; Wang D; Getzler AJ; Nguyen T; Crotty S; Wang W; Pipkin ME; Goldrath AW
Nature; 2017 Dec; 552(7684):253-257. PubMed ID: 29211713
[TBL] [Abstract][Full Text] [Related]
7. Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens.
Schlabach MR; Lin S; Collester ZR; Wrocklage C; Shenker S; Calnan C; Xu T; Gannon HS; Williams LJ; Thompson F; Dunbar PR; LaMothe RA; Garrett TE; Colletti N; Hohmann AF; Tubo NJ; Bullock CP; Le Mercier I; Sofjan K; Merkin JJ; Keegan S; Kryukov GV; Dugopolski C; Stegmeier F; Wong K; Sharp FA; Cadzow L; Benson MJ
J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 38099496
[TBL] [Abstract][Full Text] [Related]
8. Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.
Stromnes IM; Fowler C; Casamina CC; Georgopolos CM; McAfee MS; Schmitt TM; Tan X; Kim TD; Choi I; Blattman JN; Greenberg PD
J Immunol; 2012 Aug; 189(4):1812-25. PubMed ID: 22798667
[TBL] [Abstract][Full Text] [Related]
9. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.
Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Dudley ME; Somerville R; Wunderlich JR; Sherry RM; Yang JC; Rosenberg SA; Kammula US
Clin Cancer Res; 2015 Feb; 21(3):534-43. PubMed ID: 25424856
[TBL] [Abstract][Full Text] [Related]
10. Marked anti-tumor effects of CD8(+)CD62L(+) T cells from melanoma-bearing mice.
Liao Y; Geng P; Tian Y; Miao H; Liang H; Zeng R; Ni B; Ruan Z
Immunol Invest; 2015; 44(2):147-63. PubMed ID: 25122543
[TBL] [Abstract][Full Text] [Related]
11. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells.
Seo H; González-Avalos E; Zhang W; Ramchandani P; Yang C; Lio CJ; Rao A; Hogan PG
Nat Immunol; 2021 Aug; 22(8):983-995. PubMed ID: 34282330
[TBL] [Abstract][Full Text] [Related]
12. Disrupting Roquin-1 interaction with Regnase-1 induces autoimmunity and enhances antitumor responses.
Behrens G; Edelmann SL; Raj T; Kronbeck N; Monecke T; Davydova E; Wong EH; Kifinger L; Giesert F; Kirmaier ME; Hohn C; de Jonge LS; Pisfil MG; Fu M; Theurich S; Feske S; Kawakami N; Wurst W; Niessing D; Heissmeyer V
Nat Immunol; 2021 Dec; 22(12):1563-1576. PubMed ID: 34811541
[TBL] [Abstract][Full Text] [Related]
13. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
14. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
15. Adoptive Transfer of Interleukin-21-stimulated Human CD8+ T Memory Stem Cells Efficiently Inhibits Tumor Growth.
Chen Y; Yu F; Jiang Y; Chen J; Wu K; Chen X; Lin Y; Zhang H; Li L; Zhang Y
J Immunother; 2018; 41(6):274-283. PubMed ID: 29864078
[TBL] [Abstract][Full Text] [Related]
16. A
Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
[TBL] [Abstract][Full Text] [Related]
17. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
Tähtinen S; Blattner C; Vähä-Koskela M; Saha D; Siurala M; Parviainen S; Utikal J; Kanerva A; Umansky V; Hemminki A
J Immunother; 2016; 39(9):343-354. PubMed ID: 27741089
[TBL] [Abstract][Full Text] [Related]
18. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
[TBL] [Abstract][Full Text] [Related]
19. Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma.
Effern M; Glodde N; Braun M; Liebing J; Boll HN; Yong M; Bawden E; Hinze D; van den Boorn-Konijnenberg D; Daoud M; Aymans P; Landsberg J; Smyth MJ; Flatz L; Tüting T; Bald T; Gebhardt T; Hölzel M
Immunity; 2020 Sep; 53(3):564-580.e9. PubMed ID: 32750334
[TBL] [Abstract][Full Text] [Related]
20. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.
Huang J; Kerstann KW; Ahmadzadeh M; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
J Immunol; 2006 Jun; 176(12):7726-35. PubMed ID: 16751420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
